Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease.
about
The fitness cost of antibiotic resistance in Streptococcus pneumoniae: insight from the fieldMathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement?Contribution of vaccines to our understanding of pneumococcal disease.Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a modelling study based on data from PCV10 introduction in Kilifi, KenyaEffect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study.The status of invasive pneumococcal disease among children younger than 5 years of age in north-west Lombardy, Italy.Linking data and models: the importance of statistical analyses to inform models for the transmission dynamics of infections.Protecting against pneumococcal disease: critical interactions between probiotics and the airway microbiome.The two variants of the Streptococcus pneumoniae pilus 1 RrgA adhesin retain the same function and elicit cross-protection in vivo.Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model.Pneumococcal transmission and disease in silico: a microsimulation model of the indirect effects of vaccination.Natural antibodies against several pneumococcal virulence proteins in children during the pre-pneumococcal-vaccine era: the generation R study.Structural and functional characterization of the Streptococcus pneumoniae RrgB pilus backbone D1 domain.Optimal serotype compositions for Pneumococcal conjugate vaccination under serotype replacement.Optimising assessments of the epidemiological impact in The Netherlands of paediatric immunisation with 13-valent pneumococcal conjugate vaccine using dynamic transmission modelling.The serotype distribution among healthy carriers before vaccination is essential for predicting the impact of pneumococcal conjugate vaccine on invasive disease.Vaccination Drives Changes in Metabolic and Virulence Profiles of Streptococcus pneumoniae.Interaction of Vaccination and Reduction of Antibiotic Use Drives Unexpected Increase of Pneumococcal Meningitis.Comparative analysis of the humoral immune response to Moraxella catarrhalis and Streptococcus pneumoniae surface antigens in children suffering from recurrent acute otitis media and chronic otitis media with effusion.Characteristics of serogroup 20 S.pneumoniae isolates from Brazil.Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysisGeographic variation in pneumococcal vaccine efficacy estimated from dynamic modeling of epidemiological data post-PCV7Estimating rates of carriage acquisition and clearance and competitive ability for pneumococcal serotypes in Kenya with a Markov transition model.A mathematical model of serotype replacement in pneumococcal carriage following vaccination.Exploring the population-level impact of MenB vaccination via modeling: Potential for serogroup replacement.Age-dependent prevalence of nasopharyngeal carriage of streptococcus pneumoniae before conjugate vaccine introduction: a prediction model based on a meta-analysisPaediatric pneumococcal disease in Central Europe.Dynamic models for health economic assessments of pertussis vaccines: what goes around comes around....Otitis media among high-risk populations: can probiotics inhibit Streptococcus pneumoniae colonisation and the risk of disease?Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples.Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review.First human challenge testing of a pneumococcal vaccine. Double-blind randomized controlled trial.Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.Modeling and predicting the long-term effects of various strategies and objectives of varicella-zoster vaccination campaigns.Dysbiosis, Spleen Qi, Phlegm, and Complex DifficultiesExploring the role of competition induced by non-vaccine serotypes for herd protection following pneumococcal vaccination.Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine.The impact of specific and non-specific immunity on the ecology of Streptococcus pneumoniae and the implications for vaccination.
P2860
Q28478903-FDFA437E-0E2F-44B2-83E1-6B328E767728Q28727057-78C96B64-D28B-44F4-86A7-6B8B7A01CDE9Q28743870-F4CE01D4-9AE1-477A-A639-356C67232F92Q30406750-2B603579-1E31-48DA-BAF1-9839AC17309EQ33776584-82BD49C9-6042-4518-8066-C0A7B2157084Q33869370-997358BC-A3A1-48BB-AF43-3C7AD8DF2471Q34254800-F9A7AD1F-8B33-4FC7-AE26-2A34777642B8Q34290122-D25EC394-70BF-4836-947D-08A09281FC07Q34299362-56DCC000-8D67-4096-88DC-E882C67B7EF5Q34309687-C9332212-862F-4C16-A3C8-C944D8F2BCECQ34407129-2ADCC27D-2563-4B4C-B6F9-7211D0BD64C3Q34471089-741AD485-BDC7-4C65-BE18-5CF9DB6A0AD1Q34606511-571F5D8F-D34D-4198-905F-F943CFF7DE6EQ34740228-EB3DC9CE-F795-4E68-8203-9B3771DA0FACQ34800446-8900052C-E715-44F4-9658-C37ED6CE4230Q35097094-FEBDEE6F-4BD1-42FB-9322-AADB5913CB04Q35138184-464226C6-89C0-4827-8D02-BCFFA8D7259FQ35603351-96413656-AE1E-408B-9FC7-33F8E57F518EQ35693577-2C97B293-B8ED-40C5-B281-D8A7C39332AFQ35716556-F4E28EEB-956A-4772-A2FC-76F86E3A4D91Q36017775-86CC17C8-F439-46D6-ADCA-E55B78DFE5F9Q36104413-C9FEE6DD-8F1A-4EAF-BEB3-1625618A4459Q36350368-74A257E4-73F3-485E-98DB-C7838456190DQ36399999-6A3C9AF5-0F9D-4C9D-8113-34C7448257B4Q36894814-FAF2D875-CD62-4D81-A277-77AA8DF53F6AQ37255818-40877CE0-32EB-4A17-B2CA-095E22652083Q37309237-B3EA4C00-A9F3-4977-9307-E22B763CFCF5Q37509931-2636D813-1B97-4647-A448-7685695AD5C9Q37888543-9DDE1A35-977E-41B7-920E-78003B0B972FQ38068468-9C675B60-9DF9-40AE-9467-EC0CBFB2DC3DQ38091357-C43EEBD2-F393-4D2A-B6E3-FE2BFC1FC192Q38105340-6C22D800-09A7-45A7-B6E8-C9F682E7FD00Q38924170-69926114-114F-4389-BA7E-E63B9E46D014Q38950882-51BD3DE8-2194-4624-856D-7CABE448C2E9Q39976528-19F74DC7-D587-4708-BA7F-84DC57D933B8Q40686391-C6B1177B-9BAD-40B9-BD9F-F25C059930C1Q41027606-437A412E-3ACF-415F-8DEB-D9D47DD0F28BQ47115918-6320C4B0-B566-412B-A173-DA0277B35302Q47429883-21CA822F-D6C6-4219-81CD-B906ED85DDAEQ51157834-03864425-EC13-4F35-AE87-0CA4382C727C
P2860
Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Dynamic models of pneumococcal ...... invasive pneumococcal disease.
@ast
Dynamic models of pneumococcal ...... invasive pneumococcal disease.
@en
Dynamic models of pneumococcal ...... invasive pneumococcal disease.
@nl
type
label
Dynamic models of pneumococcal ...... invasive pneumococcal disease.
@ast
Dynamic models of pneumococcal ...... invasive pneumococcal disease.
@en
Dynamic models of pneumococcal ...... invasive pneumococcal disease.
@nl
prefLabel
Dynamic models of pneumococcal ...... invasive pneumococcal disease.
@ast
Dynamic models of pneumococcal ...... invasive pneumococcal disease.
@en
Dynamic models of pneumococcal ...... invasive pneumococcal disease.
@nl
P2093
P2860
P356
P1476
Dynamic models of pneumococcal ...... invasive pneumococcal disease.
@en
P2093
Elizabeth Miller
Nigel J Gay
Robert George
Yoon Hong Choi
P2860
P2888
P356
10.1186/1471-2334-10-90
P577
2010-04-08T00:00:00Z